Pfizer, Merck Execs Share Emerging Markets Strategies - Windhover's Pharmaceutical Strategic Alliances Conference (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
During the recent Pharmaceutical Strategic Alliances Conference in New York, Pfizer's Emerging Markets Business Unit President Jean-Michel Halfon and Merck's Chief Strategy Officer and Emerging Markets R&D Senior VP Merv Turner discussed priorities in tackling emerging markets. In part one, the execs outlined the steps companies should take to set up operations in emerging markets and in this second part they share their experiences in building a presence in China.
You may also be interested in...
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Although the fast-growing South African pharmaceutical market is dominated by local generic firms, multinational pharma companies are also seeing significant growth through new initiatives and product launches, said investment firm Credit Suisse in a September report based on IMS Health data
Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies